bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figures from Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy
Authors: Sterman Daniel H. , Alley Evan , Stevenson James P. , Friedberg Joseph , Metzger Susan , Recio Adri , Moon Edmund K. , Haas Andrew R. , Vachani Anil , Katz Sharyn I. , Sun Jing , Heitjan Daniel F. , Hwang Wei-Ting , Litzky Leslie , Yearley Jennifer H. , Tan Kay See , Papasavvas Emmanouil , Kennedy Paul , Montaner Luis J. , Cengel Keith A. , Simone Charles B. , Culligan Melissa , Langer Corey J. , Albelda Steven M.
Published: April 2023

Supplemental Figure 1. Immunoblots of Patient Serum before and after Therapy Supplemental Figure 2. Distribution of 1/Nab Titers for the 40 Patients Supplemental Figure 3. Distribution of the Day 2 serum levels of Interferon-alpha Supplemental Figure 4. Lack of Correlation of lymphocyte or macrophage infiltration with survival. Supplemental Figure 5. Lack of Correlation of PDL1 staining with survival. Supplemental Figure 6. Correlation of the mRNA immunoscore with survival.
Supplementary Table 4 from Whole-Exome Sequencing of Muscle-Invasive Bladder Cancer Identifies Recurrent Mutations of UNC5C and Prognostic Importance of DNA Repair Gene Mutations on Survival
Authors: Yap Kai Lee , Kiyotani Kazuma , Tamura Kenji , Antic Tatjana , Jang Miran , Montoya Magdeline , Campanile Alexa , Yew Poh Yin , Ganshert Cory , Fujioka Tomoaki , Steinberg Gary D. , O'Donnell Peter H. , Nakamura Yusuke
Published: April 2023

Genes calculated to be significantly mutated by MutSigCV algorithm (p<0.01).
Table S6 from Circulating pEGFR Is a Candidate Response Biomarker of Cetuximab Therapy in Colorectal Cancer
Authors: Katsila Theodora , Juliachs Mercè , Gregori Josep , Macarulla Teresa , Villarreal Laura , Bardelli Alberto , Torrance Chris , Elez Elena , Tabernero Josep , Villanueva Josep
Published: April 2023

List of differentially secreted proteins between the EGF_cetuximab and EGF secretomes of SW48 parental cells in 2D
Supplementary figures from Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses
Authors: Sundaresan Tilak K. , Sequist Lecia V. , Heymach John V. , Riely Gregory J. , Jänne Pasi A. , Koch Walter H. , Sullivan James P. , Fox Douglas B. , Maher Robert , Muzikansky Alona , Webb Andrew , Tran Hai T. , Giri Uma , Fleisher Martin , Yu Helena A. , Wei Wen , Johnson Bruce E. , Barber Thomas A. , Walsh John R. , Engelman Jeffrey A. , Stott Shannon L. , Kapur Ravi , Maheswaran Shyamala , Toner Mehmet , Haber Daniel A.
Published: April 2023

Supplementary Figures S1-S3. Supplementary Figure S1: T790M CTC PointMan genotyping assay. Supplementary Figure S2: T790M concordance by genotyping method. Supplementary Figure S3: Concordance of L858R and Ex 19 deletion genotyping by ctDNA and tissue biopsy.
Supplemental figure 3: Comparison of sensitivity of 18 DLBCL cell lines to HHT and ABT-199. from Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma
Authors: Klanova Magdalena , Andera Ladislav , Brazina Jan , Svadlenka Jan , Benesova Simona , Soukup Jan , Prukova Dana , Vejmelkova Dana , Jaksa Radek , Helman Karel , Vockova Petra , Lateckova Lucie , Molinsky Jan , Maswabi Bokang Calvin Lenyeletse , Alam Mahmudul , Kodet Roman , Pytlik Robert , Trneny Marek , Klener Pavel
Published: April 2023

Viability of DLBCL cell lines cultured with different concentrations of HHT (nM) or ABT-199 (Ã‚ÂµM) was measured by WST-8 survival/proliferation assay for 7-14 days. Graphs indicate % of viable cells, i.e. % of maximal absorbance of untreated cells shown with dashed lines. Representative example of two independent experiments is shown. Standard deviations were < 5% for all measurements.
supplementary figure 2 from Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab
Authors: Napolitano Stefania , Martini Giulia , Rinaldi Barbara , Martinelli Erika , Donniacuo Maria , Berrino Liberato , Vitagliano Donata , Morgillo Floriana , Barra Giusy , De Palma Raffaele , Merolla Francesco , Ciardiello Fortunato , Troiani Teresa
Published: April 2023

supplementary figure 2. Effects of cetuximab in combination with regorafenib in a panel of CRC cell lines with primary and acquired resistance to anti-EGFR inhibitor in vitro.
Supplementary methods, patient information and figure legends from Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients
Authors: Garner Andrew P. , Gozgit Joseph M. , Anjum Rana , Vodala Sadanand , Schrock Alexa , Zhou Tianjun , Serrano Cesar , Eilers Grant , Zhu Meijun , Ketzer Julia , Wardwell Scott , Ning Yaoyu , Song Youngchul , Kohlmann Anna , Wang Frank , Clackson Tim , Heinrich Michael C. , Fletcher Jonathan A. , Bauer Sebastian , Rivera Victor M.
Published: April 2023

Supplementary methods, patient information and figure legends
Supplemental Table S4 from Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas
Authors: Morin Ryan D. , Assouline Sarit , Alcaide Miguel , Mohajeri Arezoo , Johnston Rebecca L. , Chong Lauren , Grewal Jasleen , Yu Stephen , Fornika Daniel , Bushell Kevin , Nielsen Torsten Holm , Petrogiannis-Haliotis Tina , Crump Michael , Tosikyan Axel , Grande Bruno M. , MacDonald David , Rousseau Caroline , Bayat Maryam , Sesques Pierre , Froment Remi , Albuquerque Marco , Monczak Yury , Oros Kathleen Klein , Greenwood Celia , Riazalhosseini Yasser , Arseneault Madeleine , Camlioglu Errol , Constantin André , Pan-Hammarstrom Qiang , Peng Roujun , Mann Koren K. , Johnson Nathalie A.
Published: April 2023

targeted sequencing results of rrDLBCL
Supplemental Table S3 from Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas
Authors: Morin Ryan D. , Assouline Sarit , Alcaide Miguel , Mohajeri Arezoo , Johnston Rebecca L. , Chong Lauren , Grewal Jasleen , Yu Stephen , Fornika Daniel , Bushell Kevin , Nielsen Torsten Holm , Petrogiannis-Haliotis Tina , Crump Michael , Tosikyan Axel , Grande Bruno M. , MacDonald David , Rousseau Caroline , Bayat Maryam , Sesques Pierre , Froment Remi , Albuquerque Marco , Monczak Yury , Oros Kathleen Klein , Greenwood Celia , Riazalhosseini Yasser , Arseneault Madeleine , Camlioglu Errol , Constantin André , Pan-Hammarstrom Qiang , Peng Roujun , Mann Koren K. , Johnson Nathalie A.
Published: April 2023

exome sequencing results of rrDLBCL
Supplemental Materials from Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas
Authors: Morin Ryan D. , Assouline Sarit , Alcaide Miguel , Mohajeri Arezoo , Johnston Rebecca L. , Chong Lauren , Grewal Jasleen , Yu Stephen , Fornika Daniel , Bushell Kevin , Nielsen Torsten Holm , Petrogiannis-Haliotis Tina , Crump Michael , Tosikyan Axel , Grande Bruno M. , MacDonald David , Rousseau Caroline , Bayat Maryam , Sesques Pierre , Froment Remi , Albuquerque Marco , Monczak Yury , Oros Kathleen Klein , Greenwood Celia , Riazalhosseini Yasser , Arseneault Madeleine , Camlioglu Errol , Constantin André , Pan-Hammarstrom Qiang , Peng Roujun , Mann Koren K. , Johnson Nathalie A.
Published: April 2023

Supplemental methods Supplemental Figures Supplemental Figure S1. Overview of somatic copy number alterations in rrDLBCLs. Supplemental Figure S2. Consistent low coverage in the first exon of FOXO1. Supplemental Figure S3. Overview of FOXO1 mutations in rrDLBCLs. Supplemental Figure S4. VAFs corrected using purity estimates. Supplemental Figure S5. Somatic copy number alterations affecting lymphoma-related genes. Supplemental Figure S6: Recurrent deletions in NFKBIE. Supplemental Tables Supplemental Table S1. Clinical details and sample processing of 38 patients with relapsed or refractory DLBCL and TLy Supplemental Table S2. Characteristics of samples used for exome sequencing and targeted sequencing of selected genes.
Figure S2 from Notch1 Signaling Regulates the Aggressiveness of Differentiated Thyroid Cancer and Inhibits SERPINE1 Expression
Authors: Yu Xiao-Min , Jaskula-Sztul Renata , Georgen Maria R. , Aburjania Zviadi , Somnay Yash R. , Leverson Glen , Sippel Rebecca S. , Lloyd Ricardo V. , Johnson Brian P. , Chen Herbert
Published: April 2023

Scratch of a gap for wound healing assay was generated and closure of the gap was evaluated 24 hours later in FTC236-Notch1 cells with or without doxycycline treatment. The cells with NICD induction by doxycycline exhibited slower closure of the gap than those without NICD induction. Images were taken immediately after scratching the cultures 0 hr and 24hr later. Representative images at 0 hr and 24 hr are shown in the upper panel. The bar graph represents the average percentage of the gap closure. Each bar represents mean{plus minus} SEM; "Dox" indicates doxycycline; ** indicates p< 0.01; Scale bar:200µm.
Supplementary Figure 1 from Pathological T0 Following Cisplatin-Based Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Network Meta-analysis
Authors: Kim Hyung Suk , Jeong Chang Wook , Kwak Cheol , Kim Hyeon Hoe , Ku Ja Hyeon
Published: April 2023

Network geometry of the connected network of studies that evaluated pathological complete response. The circles represent the regimen as a node in the network. The lines represent direct comparisons between studies. The line thickness represents the number of studies that were included in each comparison. (A) Radical cystectomy alone. (B) Methotrexate/vinblastine/Adriamycin®/cisplatin regimen. (C) Cisplatin/methotrexate regimen. (D) Cisplatin/methotrexate/vinblastine regimen. (E) Gemcitabine/cisplatin regimen.
supplemental figure legend from FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma
Authors: Koole Koos , Brunen Diede , van Kempen Pauline M.W. , Noorlag Rob , de Bree Remco , Lieftink Cor , van Es Robert J.J. , Bernards René , Willems Stefan M.
Published: April 2023

supplemental figure legend
Supplementary Figure S1. FGFR1 protein expression and FGFR1 gene copy-numbers in HPV-positive and HPV-negative head and neck squamous cell carcinoma. from FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma
Authors: Koole Koos , Brunen Diede , van Kempen Pauline M.W. , Noorlag Rob , de Bree Remco , Lieftink Cor , van Es Robert J.J. , Bernards René , Willems Stefan M.
Published: April 2023

(A) FGFR1 protein overexpression and low FGFR1 expression in HPV-positive and HPV-negative head and neck squamous cell carcinoma patients. FGFR1 protein was overexpressed in 82% of HPV-positive and 75% of HPV-negative head and neck squamous cell carcinoma. (B) FGFR1 gene copy-numbers in HPV-positive and HPV-negative head and neck squamous cell carcinoma patients. 3% of FGFR1-overexpressing HPV-negative head and neck squamous cell carcinoma had FGFR1 amplification, 5% had a copy-number gain and 92% had normal gene copy-numbers. All FGFR1-overexpressing HPV-positive head and neck squamous cell carcinoma had normal FGFR1 gene copy-numbers. (C) The Kaplan-Meier overall survival curve for FGFR1 protein overexpression shows no relationship with survival for HPV-positive head and neck squamous cell carcinoma patients (FGFR1 overexpression: 7/33 events, low FGFR1 expression: 2/8 events). Overall survival time was missing for one patient, tissue microarray cores were unavailable for one tumor and two patients were excluded from survival analysis because they were treated with palliative intent. (D) The Kaplan-Meier disease-free survival curve also shows no relationship with survival for HPV-positive head and neck squamous cell carcinoma (FGFR1 overexpression: 10/33 events, low FGFR1 expression: 1/7 events). Disease-free survival time was missing for two patients, tissue microarray cores were unavailable for one tumor and two patients were excluded from survival analysis because they were treated with palliative intent.
Supplementary Table 3S from A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis
Authors: Hawkins Robert E. , Gore Martin , Shparyk Yaroslav , Bondar Vladimir , Gladkov Oleg , Ganev Tosho , Harza Mihai , Polenkov Serhii , Bondarenko Igor , Karlov Petr , Karyakin Oleg , Khasanov Rustem , Hedlund Gunnar , Forsberg Goran , Nordle Örjan , Eisen Timothy
Published: April 2023

Cox regression analysis with interaction between baseline covariates and treatment.
Supplementary Table 1 from Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins
Authors: Sanmamed Miguel F. , Carranza-Rua Omar , Alfaro Carlos , Oñate Carmen , Martín-Algarra Salvador , Perez Guiomar , Landazuri Sara F. , Gonzalez Álvaro , Gross Stefanie , Rodriguez Inmaculada , Muñoz-Calleja Cecilia , Rodríguez-Ruiz María , Sangro Bruno , López-Picazo José M. , Rizzo Manglio , Mazzolini Guillermo , Pascual Juan I. , Andueza Maria Pilar , Perez-Gracia Jose Luis , Melero Ignacio
Published: April 2023

Supplementary Table 1. Patient description 1
Supplementary Table 1S from A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis
Authors: Hawkins Robert E. , Gore Martin , Shparyk Yaroslav , Bondar Vladimir , Gladkov Oleg , Ganev Tosho , Harza Mihai , Polenkov Serhii , Bondarenko Igor , Karlov Petr , Karyakin Oleg , Khasanov Rustem , Hedlund Gunnar , Forsberg Goran , Nordle Örjan , Eisen Timothy
Published: April 2023

Baseline anti-SEA/E-120 and plasma concentration of Nap Day 1 at 1h in different territories.
Supplementary Figure 5S from A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis
Authors: Hawkins Robert E. , Gore Martin , Shparyk Yaroslav , Bondar Vladimir , Gladkov Oleg , Ganev Tosho , Harza Mihai , Polenkov Serhii , Bondarenko Igor , Karlov Petr , Karyakin Oleg , Khasanov Rustem , Hedlund Gunnar , Forsberg Goran , Nordle Örjan , Eisen Timothy
Published: April 2023

Anti-SEA/E-120 vs IL-2 day 1 3h. Concentration of induced IL-2 after Nap at day 1 of treatment. Moving median of 8 overlapping subgroups of patients with different baseline anti-SEA/E-120 (pmol/mL). Median{plus minus}SE is depicted.
Supplementary Figure 4S from A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis
Authors: Hawkins Robert E. , Gore Martin , Shparyk Yaroslav , Bondar Vladimir , Gladkov Oleg , Ganev Tosho , Harza Mihai , Polenkov Serhii , Bondarenko Igor , Karlov Petr , Karyakin Oleg , Khasanov Rustem , Hedlund Gunnar , Forsberg Goran , Nordle Örjan , Eisen Timothy
Published: April 2023

Cytokine response after Nap treatment in ITT and the subgroup SG patients during cycle 1 (week 1), cycle 2 (week 9) and cycle 3 (week 17). IL-2 (A). IL-6 (B). IL-10 (C). IFN-Ï’ (D). TNF-Î± (E). Geomean{plus minus}SE is depicted.
Supplemental Legend from Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins
Authors: Sanmamed Miguel F. , Carranza-Rua Omar , Alfaro Carlos , Oñate Carmen , Martín-Algarra Salvador , Perez Guiomar , Landazuri Sara F. , Gonzalez Álvaro , Gross Stefanie , Rodriguez Inmaculada , Muñoz-Calleja Cecilia , Rodríguez-Ruiz María , Sangro Bruno , López-Picazo José M. , Rizzo Manglio , Mazzolini Guillermo , Pascual Juan I. , Andueza Maria Pilar , Perez-Gracia Jose Luis , Melero Ignacio
Published: April 2023

Supplemental Legend
Table S2 from The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia
Authors: Matas-Céspedes Alba , Vidal-Crespo Anna , Rodriguez Vanina , Villamor Neus , Delgado Julio , Giné Eva , Roca-Ho Heleia , Menéndez Pablo , Campo Elías , López-Guillermo Armando , Colomer Dolors , Roué Gaël , Wiestner Adrian , Parren Paul W.H.I. , Doshi Parul , van Bueren Jeroen Lammerts , Pérez-Galán Patricia
Published: April 2023

Table S2. Mean Fluorescence Ratios (MFIR) of CD38 and CRPs
Supplementary Table from Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients
Authors: Wang Peilu , Bahreini Amir , Gyanchandani Rekha , Lucas Peter C. , Hartmaier Ryan J. , Watters Rebecca J. , Jonnalagadda Amruth R. , Trejo Bittar Humberto E. , Berg Aaron , Hamilton Ronald L. , Kurland Brenda F. , Weiss Kurt R. , Mathew Aju , Leone Jose Pablo , Davidson Nancy E. , Nikiforova Marina N. , Brufsky Adam M. , Ambros Tadeu F. , Stern Andrew M. , Puhalla Shannon L. , Lee Adrian V. , Oesterreich Steffi
Published: April 2023

Table S1. Sequence of targeted amplification primers. Table S2. Sequence of ddPCR primer and probes. Table S3. Cellularity and location of bone metastases.
Supplemental methods from The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia
Authors: Matas-Céspedes Alba , Vidal-Crespo Anna , Rodriguez Vanina , Villamor Neus , Delgado Julio , Giné Eva , Roca-Ho Heleia , Menéndez Pablo , Campo Elías , López-Guillermo Armando , Colomer Dolors , Roué Gaël , Wiestner Adrian , Parren Paul W.H.I. , Doshi Parul , van Bueren Jeroen Lammerts , Pérez-Galán Patricia
Published: April 2023

Methods not included in the main manuscript
Figure S4 from The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia
Authors: Matas-Céspedes Alba , Vidal-Crespo Anna , Rodriguez Vanina , Villamor Neus , Delgado Julio , Giné Eva , Roca-Ho Heleia , Menéndez Pablo , Campo Elías , López-Guillermo Armando , Colomer Dolors , Roué Gaël , Wiestner Adrian , Parren Paul W.H.I. , Doshi Parul , van Bueren Jeroen Lammerts , Pérez-Galán Patricia
Published: April 2023

Figure S4. Dynamics of human IgG concentration in daratumumab treated mice.
Figure S3 from The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia
Authors: Matas-Céspedes Alba , Vidal-Crespo Anna , Rodriguez Vanina , Villamor Neus , Delgado Julio , Giné Eva , Roca-Ho Heleia , Menéndez Pablo , Campo Elías , López-Guillermo Armando , Colomer Dolors , Roué Gaël , Wiestner Adrian , Parren Paul W.H.I. , Doshi Parul , van Bueren Jeroen Lammerts , Pérez-Galán Patricia
Published: April 2023

Figure S3. MEC2 mouse xenograft shows systemic organ infiltration.
Supplemental Table 2 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
Authors: Du Xiangnan , Lin Benjamin C. , Wang Qian-Rena , Li Hao , Ingalla Ellen , Tien Janet , Rooney Isabelle , Ashkenazi Avi , Penuel Elicia , Qing Jing
Published: April 2023

List of patient information in the phase I study.
Supplemental Figure 8 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
Authors: Du Xiangnan , Lin Benjamin C. , Wang Qian-Rena , Li Hao , Ingalla Ellen , Tien Janet , Rooney Isabelle , Ashkenazi Avi , Penuel Elicia , Qing Jing
Published: April 2023

Lack of effect of R3Mab on serum pro-MMP-10 levels in mice with SW780 tumors.
Supplementary Methods, Figure Legends and Table 1 from Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non–Small Cell Lung Cancer
Authors: Sharma Ashish , Bender Sabine , Zimmermann Martina , Riesterer Oliver , Broggini-Tenzer Angela , Pruschy Martin N.
Published: April 2023

Supplementary Methods, Figure Legends; Table S1: Human Angiogenesis Antibody Array kit (R&D Systems; ARY007)
Supplemental Figure 1 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
Authors: Du Xiangnan , Lin Benjamin C. , Wang Qian-Rena , Li Hao , Ingalla Ellen , Tien Janet , Rooney Isabelle , Ashkenazi Avi , Penuel Elicia , Qing Jing
Published: April 2023

FGFR3 knockdown reduces MMP-1 and MMP-10 mRNA expression in RT112 cells.
Supplementary Methods from Development and Validation of a Novel Radiosensitivity Signature in Human Breast Cancer
Authors: Speers Corey , Zhao Shuang , Liu Meilan , Bartelink Harry , Pierce Lori J. , Feng Felix Y.
Published: April 2023

Supplementary methods
Supplementary Figure and Table Legends from Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype
Authors: Mack Stephen C. , Agnihotri Sameer , Bertrand Kelsey C. , Wang Xin , Shih David J. , Witt Hendrik , Hill Nadia , Zayne Kory , Barszczyk Mark , Ramaswamy Vijay , Remke Marc , Thompson Yuan , Ryzhova Marina , Massimi Luca , Grajkowska Wieslawa , Lach Boleslaw , Gupta Nalin , Weiss William A. , Guha Abhijit , Hawkins Cynthia , Croul Sidney , Rutka James T. , Pfister Stefan M. , Korshunov Andrey , Pekmezci Melike , Tihan Tarik , Philips Joanna J. , Jabado Nada , Zadeh Gelareh , Taylor Michael D.
Published: April 2023

Supplementary Figure and Table Legends. Legends describing in detail the data shown in supplementary figures and tables pertaining to this manuscript.
Supplementary Figure 3 from Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype
Authors: Mack Stephen C. , Agnihotri Sameer , Bertrand Kelsey C. , Wang Xin , Shih David J. , Witt Hendrik , Hill Nadia , Zayne Kory , Barszczyk Mark , Ramaswamy Vijay , Remke Marc , Thompson Yuan , Ryzhova Marina , Massimi Luca , Grajkowska Wieslawa , Lach Boleslaw , Gupta Nalin , Weiss William A. , Guha Abhijit , Hawkins Cynthia , Croul Sidney , Rutka James T. , Pfister Stefan M. , Korshunov Andrey , Pekmezci Melike , Tihan Tarik , Philips Joanna J. , Jabado Nada , Zadeh Gelareh , Taylor Michael D.
Published: April 2023

Supplementary Figure 3. Analysis of HIF-1a expression in Spinal Grade II versus Myxopapillary Ependymoma in additional to single sample GSEA analysis of HIF1a transcriptional targets.
Supplementary Figure 1 from Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype
Authors: Mack Stephen C. , Agnihotri Sameer , Bertrand Kelsey C. , Wang Xin , Shih David J. , Witt Hendrik , Hill Nadia , Zayne Kory , Barszczyk Mark , Ramaswamy Vijay , Remke Marc , Thompson Yuan , Ryzhova Marina , Massimi Luca , Grajkowska Wieslawa , Lach Boleslaw , Gupta Nalin , Weiss William A. , Guha Abhijit , Hawkins Cynthia , Croul Sidney , Rutka James T. , Pfister Stefan M. , Korshunov Andrey , Pekmezci Melike , Tihan Tarik , Philips Joanna J. , Jabado Nada , Zadeh Gelareh , Taylor Michael D.
Published: April 2023

Supplementary Figure 1. Unsupervised consensus hierarchical clustering and non-negative matrix factorization of 35 spinal ependymoma gene expression signatures from a rank 2 to 4 classification.
Figure S3 from The MCT4 Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer
Authors: Choi Stephen Yiu Chuen , Xue Hui , Wu Rebecca , Fazli Ladan , Lin Dong , Collins Colin C. , Gleave Martin E. , Gout Peter W. , Wang Yuzhuo
Published: April 2023

Treatment of nude mice with MCT4 ASO did not cause host toxicity as measured by animal weights. A) Animal weights were monitored throughout the duration of the in vivo study, and treatment with MCT4 ASOs did not significantly affect the average animal weight of each group. B) The individual animal weights also remained stable throughout the treatment period.
Figure S2 from The MCT4 Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer
Authors: Choi Stephen Yiu Chuen , Xue Hui , Wu Rebecca , Fazli Ladan , Lin Dong , Collins Colin C. , Gleave Martin E. , Gout Peter W. , Wang Yuzhuo
Published: April 2023

Candidate MCT4 ASOs are able to inhibit PC-3 cell migration and tissue invasion in vitro. A) Treatment of PC3 cells with candidate MCT4 ASOs resulted in an inhibition of cell migration through a transwell, as indicated by a reduction in the number of migrated cells observed. B) Treatment with MCT4 ASO also inhibited the ability of PC-3 cells to invade Matrigel. As such, MCT4-mediated lactic acid secretion could play an important role in cancer metastasis.
Supplementary Table 5 from Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression
Authors: Lopez Sandra M. , Agoulnik Alexander I. , Zhang Manqi , Peterson Leif E. , Suarez Egla , Gandarillas Gregory A. , Frolov Anna , Li Rile , Rajapakshe Kimal , Coarfa Christian , Ittmann Michael M. , Weigel Nancy L. , Agoulnik Irina U.
Published: April 2023

Sequences of siRNAs and primers and probes for qPCR
Supplemental Figure 4 from High Levels of Antibody that Neutralize B-cell Infection of Epstein–Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma
Authors: Coghill Anna E. , Bu Wei , Nguyen Hanh , Hsu Wan-Lun , Yu Kelly J. , Lou Pei-Jen , Wang Cheng-Ping , Chen Chien-Jen , Hildesheim Allan , Cohen Jeffrey I.
Published: April 2023

Correlation of anti-gH/gL antibodies with anti-gp350 antibodies.
Supplementary Figure 2 from Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors
Authors: Von Hoff Daniel D. , Mita Monica M. , Ramanathan Ramesh K. , Weiss Glen J. , Mita Alain C. , LoRusso Patricia M. , Burris Howard A. , Hart Lowell L. , Low Susan C. , Parsons Donald M. , Zale Stephen E. , Summa Jason M. , Youssoufian Hagop , Sachdev Jasgit C.
Published: April 2023

Figure S2 displays a graph of the plasma concentrations of total docetaxel for patients dosed with 60/mg/m2 of BIND-014 on the Q3W schedule.
Supplementary Figures 1 - 3 from Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
Authors: Taube Janis M. , Young Geoffrey D. , McMiller Tracee L. , Chen Shuming , Salas January T. , Pritchard Theresa S. , Xu Haiying , Meeker Alan K. , Fan Jinshui , Cheadle Chris , Berger Alan E. , Pardoll Drew M. , Topalian Suzanne L.
Published: April 2023

Figure S1, Figure S2, Figure S3. Supplementary Figure S1: Overlay of PD-L1 and LAG-3 IHC demonstrates close geographic association of these cell-surface markers in a melanoma lymph node metastasis. Supplementary Figure S2: Comparison of immunohistochemistry (IHC) and in situ hybridization (ISH) for LAG-3 expression in a melanoma lymph node metastasis. Supplementary Figure S3: IL-32-g activates CD3+ T cells and induces their expression of PD-L1.
Supplementary Figure S1 from Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer
Authors: Ota Keiichi , Azuma Koichi , Kawahara Akihiko , Hattori Satoshi , Iwama Eiji , Tanizaki Junko , Harada Taishi , Matsumoto Koichiro , Takayama Koichi , Takamori Shinzo , Kage Masayoshi , Hoshino Tomoaki , Nakanishi Yoichi , Okamoto Isamu
Published: April 2023

Supplementary Figure S1. Flow cytometric histograms for PD-L1 expression at the surface of lung cancer cell lines positive or negative for the EML4-ALK fusion gene.
Supplementary Table 2 from Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
Authors: Azad Arun A. , Volik Stanislav V. , Wyatt Alexander W. , Haegert Anne , Le Bihan Stephane , Bell Robert H. , Anderson Shawn A. , McConeghy Brian , Shukin Robert , Bazov Jenny , Youngren Jack , Paris Pamela , Thomas George , Small Eric J. , Wang Yuzhuo , Gleave Martin E. , Collins Colin C. , Chi Kim N.
Published: April 2023

Supplementary Table 2. Frequency of androgen receptor (AR) copy number variation stratified by systemic therapy at time of circulating cell-free DNA (cfDNA) collection
Supplementary Figure 1, Supplementary Figure 2 from Identification of an Immunogenic Subset of Metastatic Uveal Melanoma
Authors: Rothermel Luke D. , Sabesan Arvind C. , Stephens Daniel J. , Chandran Smita S. , Paria Biman C. , Srivastava Abhishek K. , Somerville Robert , Wunderlich John R. , Lee Chyi-Chia R. , Xi Liqiang , Pham Trinh H. , Raffeld Mark , Jailwala Parthav , Kasoji Manjula , Kammula Udai S.
Published: April 2023

Supplementary Figure 1. In situ MRI assessment of tumor melanin content. Supplementary Figure 2. UM and CM liver metastases demonstrate similar immunophenotype profile.
Supplementary Figure Legends from Gain of HIF-1α under Normoxia in Cancer Mediates Immune Adaptation through the AKT/ERK and VEGFA Axes
Authors: Lee Young-Ho , Bae Hyun Cheol , Noh Kyung Hee , Song Kwon-Ho , Ye Sang-kyu , Mao Chih-Ping , Lee Kyung-Mi , Wu T.-C. , Kim Tae Woo
Published: April 2023

Supplementary Figure Legends
Supplementary Figure 2 from Rilotumumab Exposure–Response Relationship in Patients with Advanced or Metastatic Gastric Cancer
Authors: Doshi Sameer , Gisleskog Per Olsson , Zhang Yilong , Zhu Min , Oliner Kelly S. , Loh Elwyn , Ruixo Juan Jose Perez
Published: April 2023

Supplementary Figure 2. Goodness-of-Fit Plots for the Tumor Growth Model
Supplementary Figure S3a-x from Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease
Authors: Klintman Marie , Buus Richard , Cheang Maggie Chon U. , Sheri Amna , Smith Ian E. , Dowsett Mitch
Published: April 2023

Kaplan-Meier curves with probability of relapse, with genes divided into tertiles for all 24 genes for the end-point TTR for (a) ACACB (b) ALDHA1 (c) AURKA (d) BCL2 (e) BCL2L1 (f) CD3D (g) CD44 (h) CXCL14 (i) DECORIN (j) DUSP4 (k) ERBB2 (l)ESR1 (m) LDHB (n) MKI67 (o) PAWR (p) PLAU (q) SNAI1 (r) SNAI2 (s) SOX9 (t) SPARC (u) STAT1 (v) STAT3 (w) TOP2A and (x) TWIST
Supplementary Figure S2 from Clever-1/Stabilin-1 Controls Cancer Growth and Metastasis
Authors: Karikoski Marika , Marttila-Ichihara Fumiko , Elima Kati , Rantakari Pia , Hollmén Maija , Kelkka Tiina , Gerke Heidi , Huovinen Ville , Irjala Heikki , Holmdahl Rikard , Salmi Marko , Jalkanen Sirpa
Published: April 2023

Supplementary Figure S2. Genotyping of different Clever-1 targeted mice
Figure S5 from FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers
Authors: Göke Friederike , Franzen Alina , Hinz Trista K. , Marek Lindsay A. , Yoon Petros , Sharma Rakesh , Bode Maike , von Maessenhausen Anne , Lankat-Buttgereit Brigitte , Göke Antonia , Golletz Carsten , Kirsten Robert , Boehm Diana , Vogel Wenzel , Kleczko Emily K. , Eagles Justin R. , Hirsch Fred R. , Van Bremen Tobias , Bootz Friedrich , Schroeck Andreas , Kim Jihye , Tan Aik-Choon , Jimeno Antonio , Heasley Lynn E. , Perner Sven
Published: April 2023

Figure S5. In situ hybridization (ISH) assay for FGFR1 mRNA in primary HNSCC tissue.
Figure S1 from SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells
Authors: Piccione Emily C. , Juarez Silvia , Tseng Serena , Liu Jie , Stafford Melissa , Narayanan Cyndhavi , Wang Lijuan , Weiskopf Kipp , Majeti Ravindra
Published: April 2023

Supplementary Figure S1: SIRPabodies bind to CD20 and CD47 with weak affinity for CD47
Supplementary Tables 1-7 from Krüppel-like Factor 4 Blocks Hepatocellular Carcinoma Dedifferentiation and Progression through Activation of Hepatocyte Nuclear Factor-6
Authors: Sun Hongcheng , Tang Huamei , Xie Dacheng , Jia Zhiliang , Ma Zhenyu , Wei Daoyan , Mishra Lopa , Gao Yong , Zheng Shaojiang , Xie Keping , Peng Zhihai
Published: April 2023

Supplementary Table S1. Primer Information for and the Genes Studied Using Real-time PCR and RT-PCR Analysis Supplementary Table S2. KLF4 Protein Expression in HCC and Matched Nontumor Tissue Specimens (n= 98*) Supplementary Table S3. Associations Between KLF4 Expression and Clinicopathological Parameters in HCC Patients Who Underwent OLT (n = 98*) Supplementary Table S4. Differences in HNF-6 Protein Expression in HCC and Matched Nontumor Tissue Specimens (n = 99) Supplementary Table S5. Association Between HNF-6 Expression and Clinicopathological Parameters in HCC Patients Who Underwent OLT (n = 99) Supplementary Table S6. Correlation Between KLF4 and HNF-6 Protein Expression in Human HCC Specimens (n = 98â€ ) Supplementary Table S7. Univrariate and Multivariate Analysis of Parameters Related to OS and RFS in HCC Patients After OLT
Supplementary Figure 5 from Tissue Transglutaminase Mediated Tumor–Stroma Interaction Promotes Pancreatic Cancer Progression
Authors: Lee Jiyoon , Condello Salvatore , Yakubov Bakhtiyor , Emerson Robert , Caperell-Grant Andrea , Hitomi Kiyotaka , Xie Jingwu , Matei Daniela
Published: April 2023

Supplementary Figure 5. Total collagen content in pancreatic xenografts.
Supplementary Figure 4. from Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
Authors: Henssen Anton , Althoff Kristina , Odersky Andrea , Beckers Anneleen , Koche Richard , Speleman Frank , Schäfers Simon , Bell Emma , Nortmeyer Maike , Westermann Frank , De Preter Katleen , Florin Alexandra , Heukamp Lukas , Spruessel Annika , Astrahanseff Kathy , Lindner Sven , Sadowski Natalie , Schramm Alexander , Astorgues-Xerri Lucile , Riveiro Maria E. , Eggert Angelika , Cvitkovic Esteban , Schulte Johannes H.
Published: April 2023

OTX015 reduces cell proliferation and induces apoptosis in MYCN amplified human xenografts. (a) Representative pictures of IMR5 xenograft tumor sections stained with hematoxylin/eosin, and immunohistochemical staining for apoptotic cells (cleaved caspase 3) and proliferating cells (Mib-1/Ki 67) are shown. Scale bar=250 µm. The relative fraction of positively stained cells for cleaved caspase 3 (b) and Mib-1 (c) were calculated from three representative images from each xenograft tumor and are shown as box plots. Statistical difference between groups was assessed by Student's t test. * p < 0.05, ** p < 0.01, *** p < 0.001.
Supplementary Figure 1. from Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
Authors: Henssen Anton , Althoff Kristina , Odersky Andrea , Beckers Anneleen , Koche Richard , Speleman Frank , Schäfers Simon , Bell Emma , Nortmeyer Maike , Westermann Frank , De Preter Katleen , Florin Alexandra , Heukamp Lukas , Spruessel Annika , Astrahanseff Kathy , Lindner Sven , Sadowski Natalie , Schramm Alexander , Astorgues-Xerri Lucile , Riveiro Maria E. , Eggert Angelika , Cvitkovic Esteban , Schulte Johannes H.
Published: April 2023

OTX015 has no significant effect on non-malignant human fibroblasts. (a) Representative pictures of human fibroblasts treated for 72 h with 500 nM OTX015 or DMSO control. Scale bar=100 µm. (b) Growth of fibroblasts treated with 500 nM OTX015 (black) or DMSO control (grey) monitored over 96 h using the xCELLigence system. The slope (1/h) of both curves was calculated, and did not show a significant difference (right) using the Student's t test.
IMR5 Super Enhancers from Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
Authors: Henssen Anton , Althoff Kristina , Odersky Andrea , Beckers Anneleen , Koche Richard , Speleman Frank , Schäfers Simon , Bell Emma , Nortmeyer Maike , Westermann Frank , De Preter Katleen , Florin Alexandra , Heukamp Lukas , Spruessel Annika , Astrahanseff Kathy , Lindner Sven , Sadowski Natalie , Schramm Alexander , Astorgues-Xerri Lucile , Riveiro Maria E. , Eggert Angelika , Cvitkovic Esteban , Schulte Johannes H.
Published: April 2023

List of all Super-enhancers identified in IMR5 cells
Supplementary Figure 2 from Dual HER2 Targeting Impedes Growth of HER2 Gene–Amplified Uterine Serous Carcinoma Xenografts
Authors: Groeneweg Jolijn W. , Hernandez Silvia F. , Byron Virginia F. , DiGloria Celeste M. , Lopez Hector , Scialabba Vanessa , Kim Minji , Zhang Ling , Borger Darrell R. , Tambouret Rosemary , Foster Rosemary , Rueda Bo R. , Growdon Whitfield B.
Published: April 2023

Supplementary Figure 2. Anti-tumor activity of single agent lapatinib treatment was observed in HER2 amplified ARK2 xenografts (p = 0.02), while no response was seen in non-HER2 amplified SPEC2 xenografts. Mice harboring tumors derived from ARK2 or SPEC2 cell lines were treated with either vehicle or lapatinib. Tumors were measured twice weekly, and the percent change in tumor volume compared to baseline volume (100%) is shown. Error bars represent the standard error of the mean.
Supplementary Tables S1-3 from Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma
Authors: Pirazzoli Valentina , Ayeni Deborah , Meador Catherine B. , Sanganahalli Basavaraju G. , Hyder Fahmeed , de Stanchina Elisa , Goldberg Sarah B. , Pao William , Politi Katerina
Published: April 2023

Supplementary Table 1: Tumor volume measurements during treatment Supplementary Table 2: List of mice with drug-resistant tumors Supplementary Table 3: List of mice that did not develop drug resistance. Tables listing mice used in the therapeutic studies showing tumor volumes and tumor volume changes through treatment.
Supplementary Figures S1-3 from Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma
Authors: Pirazzoli Valentina , Ayeni Deborah , Meador Catherine B. , Sanganahalli Basavaraju G. , Hyder Fahmeed , de Stanchina Elisa , Goldberg Sarah B. , Pao William , Politi Katerina
Published: April 2023

Supplementary Figure 1: MRI images and tumor volume measurements. Supplementary Figure 2: Mouse body weight during drug treatment. Supplementary Figure 3: Results of molecular studies of resistant tumors.
Supplementary Tables 1-2 and Supplementary Figures 1-2 from Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer
Authors: Hingorani Sunil R. , Harris William P. , Beck J. Thaddeus , Berdov Boris A. , Wagner Stephanie A. , Pshevlotsky Eduard M. , Tjulandin Sergei A. , Gladkov Oleg A. , Holcombe Randall F. , Korn Ronald , Raghunand Natarajan , Dychter Samuel , Jiang Ping , Shepard H. Michael , Devoe Craig E.
Published: April 2023

1) Supplementary Table 1. Summary of imaging assessment. 2) Supplementary Table 2. Efficacy results by HA content and dose level of PEGPH20. 3) Supplementary Figure 1. Change from baseline in serum CA19-9 concentration for treated patients. 4) Supplementary Figure 2. Representative DCE-MRI images of 2 patients with liver metastases prior to and 24 hours following treatment with intravenous PEGPH20.
Supplemental Appendix from Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis
Authors: McConechy Melissa K. , Talhouk Aline , Leung Samuel , Chiu Derek , Yang Winnie , Senz Janine , Reha-Krantz Linda J. , Lee Cheng-Han , Huntsman David G. , Gilks C. Blake , McAlpine Jessica N.
Published: April 2023

Supplemental methods Supplemental Table S1: Clinical characteristics of all POLE mutated and POLE wild-type endometrial carcinomas Supplemental Table S2: Clinical characteristics of POLE mutated and POLE wild-type endometrial carcinomas with association tests Supplemental Table S3: Univariable survival analysis Supplemental Table S4: Multivariable survival analysis for whole cohort Supplemental Table S5: Multivariable survival analysis for grade 3 endometrioid carcinomas only Supplemental Table S6: POLE mutation and treatment interaction analysis Supplemental Table S7: Meta-analysis data extraction and source of multivariable hazard ratios from individual studies Supplemental Table S8: Meta-analysis data extraction and source of multivariable hazard ratios for grade 3 ECs Supplemental Table S9: Computed multivariable hazard ratios of POLE for VGH cohort Supplemental Table S10: Computed multivariable hazard ratios of POLE for Meng cohort Supplemental Table S11: Computed multivariable hazard ratios of POLE for TCGA cohort Supplemental Table S12: Computed multivariable hazard ratios of POLE for grade 3 ECs in VGH cohort Supplemental Table S13: Computed multivariable hazard ratios of POLE for grade 3 ECs in TCGA cohort Supplemental Figure S1A-B: Kaplan Meier plots of OS for the whole EC cohort (A) and grade 3 only (B) Supplemental Figure S2: Kaplan Meier curve for OS of POLE EDM mutated patients and POLE wild-type with and without adjuvant treatment Supplemental Figure S3A-C: Meta-analysis of pooled multivariable hazard ratios for OS of whole cohort (A), DSS for grade 3 only (B), OS for grade 3 only (C)
Supplement from HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer
Authors: Xu Chun-Fang , Johnson Toby , Wang Xiaojing , Carpenter Chris , Graves Alan P. , Warren Liling , Xue Zhengyu , King Karen S. , Fraser Dana J. , Stinnett Sandy , Briley Linda P. , Mitrica Ionel , Spraggs Colin F. , Nelson Matthew R. , Tada Hiroomi , du Bois Andreas , Powles Thomas , Kaplowitz Neil , Pandite Lini N.
Published: April 2023

Supplementary Table S1. Summary of eight pazopanib (monotherapy) clinical studies included in the discovery pharmacogenetic liver toxicity analysis Supplementary Table S2. Summary of 23 pazopanib clinical studies included in the confirmatory pharmacogenetic liver toxicity analysis Supplementary Table S3. Primary tumor types for patients in the pharmacogenetic analyses Supplementary Table S4. Association between HLA-B*57:01 carriage and ALT elevation in pazopanib-treated patients with cancer. Sensitivity analyses in the combined dataset excluding 192 patients with baseline ALT>ULN Supplementary Table S5. Assessment of patients who had concurrent ALT (>3Ã—ULN) and total bilirubin (>2Ã—ULN) elevations Supplementary Table S6. Association between rs1800625 (chr6:32152442) genotype and ALT elevation in pazopanib-treated patients with cancer Supplementary Table S7. Joint analysis of HLA-B*57:01 and rs1800625 (chr6:32152442) genotype association with time to ALT>3xULN in pazopanib-treated patients with cancer Supplementary Figure S1. Genome-wide association study (GWAS) of common genetic variants (minor allele frequency {greater than or equal to}5%) associated with time to first ALT>3Ã—ULN.
Supplementary Figure S5 from Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies
Authors: Krepler Clemens , Xiao Min , Sproesser Katrin , Brafford Patricia A. , Shannan Batool , Beqiri Marilda , Liu Qin , Xu Wei , Garman Bradley , Nathanson Katherine L. , Xu Xiaowei , Karakousis Giorgos C. , Mills Gordon B. , Lu Yiling , Ahmed Tamer A. , Poulikakos Poulikos I. , Caponigro Giordano , Boehm Markus , Peters Malte , Schuchter Lynn M. , Weeraratna Ashani T. , Herlyn Meenhard
Published: April 2023

A. heat map of complete RPPA data median centered, all tumor grafts untreated. Data are mean of 3 biological replicates, red is up, green is down. B. Principal component analysis (PCA) of median centered data C. heat map of fold change between untreated tumor grafts and on chronic BRAF inhibitor therapy. D. Principal component analysis (PCA) of fold change data.
Supplementary Figure S2 from Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy
Authors: Gradishar William J. , Yardley Denise A. , Layman Rachel , Sparano Joseph A. , Chuang Ellen , Northfelt Donald W. , Schwartz Gary N. , Youssoufian Hagop , Tang Shande , Novosiadly Ruslan , Forest Amelie , Nguyen Tuan S. , Cosaert Jan , Grebennik Dmitri , Haluska Paul
Published: April 2023

Kaplan-Meier curves of PFS and OS in pooled group and arm A dichotomized by insulin receptor-B (IR-B) expression (high vs. low) using the 75th percentile of marker distribution as cutpoint.
Supplemental Methods from Novel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate Cancer
Authors: de Leeuw Renée , Berman-Booty Lisa D. , Schiewer Matthew J. , Ciment Stephen J. , Den Robert B. , Dicker Adam P. , Kelly William K. , Trabulsi Edouard J. , Lallas Costas D. , Gomella Leonard G. , Knudsen Karen E.
Published: April 2023

Supplemental Methods from Novel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate Cancer
Supplemental Figure 3 from Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer
Authors: Moon Edmund K. , Ranganathan Raghuveer , Eruslanov Evgeniy , Kim Soyeon , Newick Kheng , O'Brien Shaun , Lo Albert , Liu Xiaojun , Zhao Yangbing , Albelda Steven M.
Published: April 2023

Expression of PDL1 on tumors.
Supplemental Figure 1 from Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer
Authors: Moon Edmund K. , Ranganathan Raghuveer , Eruslanov Evgeniy , Kim Soyeon , Newick Kheng , O'Brien Shaun , Lo Albert , Liu Xiaojun , Zhao Yangbing , Albelda Steven M.
Published: April 2023

Comparison of inhibitory receptors on CD8 and CD4 tumor infiltrating lymphocytes.
Supplemental Figure 4-6 from Novel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate Cancer
Authors: de Leeuw Renée , Berman-Booty Lisa D. , Schiewer Matthew J. , Ciment Stephen J. , Den Robert B. , Dicker Adam P. , Kelly William K. , Trabulsi Edouard J. , Lallas Costas D. , Gomella Leonard G. , Knudsen Karen E.
Published: April 2023

GO analyses of gene clusters corresponding with Figure 6A.
Supplemental Figure 2-3 from Novel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate Cancer
Authors: de Leeuw Renée , Berman-Booty Lisa D. , Schiewer Matthew J. , Ciment Stephen J. , Den Robert B. , Dicker Adam P. , Kelly William K. , Trabulsi Edouard J. , Lallas Costas D. , Gomella Leonard G. , Knudsen Karen E.
Published: April 2023

Dose response curves of CBTX and DCTX in LAPC4, VCaP and LNCaP-abl cells. C4-2 xenograft tumor growth response to CBTX in mice. Cleaved PARP western blot analysis of LNCaP and C4-2 cells treated with 1nM CBTX or DCTX.
Supplemental Figure 1 from Novel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate Cancer
Authors: de Leeuw Renée , Berman-Booty Lisa D. , Schiewer Matthew J. , Ciment Stephen J. , Den Robert B. , Dicker Adam P. , Kelly William K. , Trabulsi Edouard J. , Lallas Costas D. , Gomella Leonard G. , Knudsen Karen E.
Published: April 2023

Bivariate flow cytometry analyses of LNCaP and C4-2 cells treated with 1nM DCTX for 16 or 48h.
Supplemental data. Appendix 3. Adjusting for batch variation from The Prognostic and Predictive Value of Soluble Type IV Collagen in Colorectal Cancer: A Retrospective Multicenter Study
Authors: Rolff Hans Christian , Christensen Ib Jarle , Vainer Ben , Svendsen Lars Bo , Eefsen Rikke Løvendahl , Wilhelmsen Michael , Lund Ida Katrine , Høyer-Hansen Gunilla , Nielsen Hans Jørgen , Illemann Martin
Published: April 2023

A text document describing how we corrected for batch variation.
Supplementary file 1 from Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer
Authors: Chong Curtis R. , Bahcall Magda , Capelletti Marzia , Kosaka Takayuki , Ercan Dalia , Sim Taebo , Sholl Lynette M. , Nishino Mizuki , Johnson Bruce E. , Gray Nathanael S. , Jänne Pasi A.
Published: April 2023

Contents of the Dana-Farber Targeted Therapy Library and raw data
Supplemental Figure 5 - Pooled standard curves. from The Prognostic and Predictive Value of Soluble Type IV Collagen in Colorectal Cancer: A Retrospective Multicenter Study
Authors: Rolff Hans Christian , Christensen Ib Jarle , Vainer Ben , Svendsen Lars Bo , Eefsen Rikke Løvendahl , Wilhelmsen Michael , Lund Ida Katrine , Høyer-Hansen Gunilla , Nielsen Hans Jørgen , Illemann Martin
Published: April 2023

Shows the pooled standard curves for the two batches. Figure legend in the end the "Supplementary data. Appendix 3. Adjusting for batch variation" file.